Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
CONCLUSION: The alternation of payload achieves different responses in different settings. T-Dxd followed by RC48 may be a potentially beneficial strategy in HER2-positive disease. Further research is needed to elucidate the mechanism of cross-resistance.PMID:38574190 | DOI:10.1093/oncolo/oyae055 (Source: The Oncologist)
Source: The Oncologist - April 4, 2024 Category: Cancer & Oncology Authors: Meiting Chen Riqing Huang Rishang Chen Fei Pan Xiujiao Shen Haifeng Li Qixiang Rong Xin An Cong Xue Yanxia Shi Source Type: research

Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
CONCLUSION: The alternation of payload achieves different responses in different settings. T-Dxd followed by RC48 may be a potentially beneficial strategy in HER2-positive disease. Further research is needed to elucidate the mechanism of cross-resistance.PMID:38574190 | DOI:10.1093/oncolo/oyae055 (Source: The Oncologist)
Source: The Oncologist - April 4, 2024 Category: Cancer & Oncology Authors: Meiting Chen Riqing Huang Rishang Chen Fei Pan Xiujiao Shen Haifeng Li Qixiang Rong Xin An Cong Xue Yanxia Shi Source Type: research

Factors Influencing Adherence to the Risk Management Program for Women With a Genetic Predisposition to Breast Cancer: Real-World Data from a French Multicenter Program
CONCLUSION: Having a higher BC risk status does not result in better adherence to the risk management program. However, factors directly related to screening rounds reduced postponements. Future research should address the benefits of screening-related organizational factors that contribute to adherence improvement.PMID:38564263 | DOI:10.1093/oncolo/oyae057 (Source: The Oncologist)
Source: The Oncologist - April 2, 2024 Category: Cancer & Oncology Authors: Ke Zhou Martine Bellanger Louise Crivelli Sandy Laham Charlotte Huet Caroline Abadie Source Type: research

Factors Influencing Adherence to the Risk Management Program for Women With a Genetic Predisposition to Breast Cancer: Real-World Data from a French Multicenter Program
CONCLUSION: Having a higher BC risk status does not result in better adherence to the risk management program. However, factors directly related to screening rounds reduced postponements. Future research should address the benefits of screening-related organizational factors that contribute to adherence improvement.PMID:38564263 | DOI:10.1093/oncolo/oyae057 (Source: The Oncologist)
Source: The Oncologist - April 2, 2024 Category: Cancer & Oncology Authors: Ke Zhou Martine Bellanger Louise Crivelli Sandy Laham Charlotte Huet Caroline Abadie Source Type: research

Storage, Disposal, and Use of Opioids Among Cancer Patients in Central China: A Multi-Center Cross-Sectional Study
CONCLUSION: A significant proportion of Chinese patients with cancer exhibit unsafe practices in the storage, disposal, and use of opioids. The study highlights an urgent need for implementing routine education programs and drug "take-back" initiatives to improve opioid-related practices.PMID:38557816 | DOI:10.1093/oncolo/oyae049 (Source: The Oncologist)
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Mi Zhang Huili Chen Chenxi Luo Xuanxuan Wang Liang Liu Dongfang Wu Hong Cheng Source Type: research

Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial
CONCLUSIONS: EPC is associated with a significant improvement in OS, although, we observed that the greatest benefit of providing EPC was observed in those with a global QoL > 70 at baseline. This study did not identify significant changes in terms of QoL or symptom burden between the study groups after follow-up. Evidence robustly suggests that EPC should be considered part of the multidisciplinary treatment of metastatic NSCLC patients since diagnosis. According to our study, EPC can be implemented in low- or middle-income countries (LMIC).PMID:38558247 | DOI:10.1093/oncolo/oyae050 (Source: The Oncologist)
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Silvia Allende Jenny G Turcott Emma Ver ástegui Oscar Rodr íguez-Mayoral Diana Flores-Estrada Dana Aline P érez Camargo Maritza Ramos-Ram írez Jorge-Negueb Mart ínez-Hernández Luis F O ñate-Ocaña Pamela Soberanis Pina Andr és F Cardona Oscar Arri Source Type: research

Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Oncologist. 2024 Apr 1:oyae044. doi: 10.1093/oncolo/oyae044. Online ahead of print.ABSTRACTWe analyzed the antitumor activity of platinum-based chemotherapies and then immune checkpoint inhibitors (ICI) in all-comers patients with solid tumors having a somatic DNA damage repair gene alteration (DDR-GA) identified through a prospective precision medicine study (NCT02534649). Each DDR-GA was classified as pathogenic (Pa), probably pathogenic (PPa), and unknown pathogenicity (UPa) according to OncoKB and ClinVAR databases. Between January 2018 and May 2020, 662 patients were screened. One hundred ninety-nine tumors with DDR-G...
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Cl ément Chabot Antoine Italiano Amandine Cromb é Isabelle Soubeyran Yech'an Laizet Emmanuel Khalifa Sophie Cousin Source Type: research

Storage, Disposal, and Use of Opioids Among Cancer Patients in Central China: A Multi-Center Cross-Sectional Study
CONCLUSION: A significant proportion of Chinese patients with cancer exhibit unsafe practices in the storage, disposal, and use of opioids. The study highlights an urgent need for implementing routine education programs and drug "take-back" initiatives to improve opioid-related practices.PMID:38557816 | DOI:10.1093/oncolo/oyae049 (Source: The Oncologist)
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Mi Zhang Huili Chen Chenxi Luo Xuanxuan Wang Liang Liu Dongfang Wu Hong Cheng Source Type: research

Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial
CONCLUSIONS: EPC is associated with a significant improvement in OS, although, we observed that the greatest benefit of providing EPC was observed in those with a global QoL > 70 at baseline. This study did not identify significant changes in terms of QoL or symptom burden between the study groups after follow-up. Evidence robustly suggests that EPC should be considered part of the multidisciplinary treatment of metastatic NSCLC patients since diagnosis. According to our study, EPC can be implemented in low- or middle-income countries (LMIC).PMID:38558247 | DOI:10.1093/oncolo/oyae050 (Source: The Oncologist)
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Silvia Allende Jenny G Turcott Emma Ver ástegui Oscar Rodr íguez-Mayoral Diana Flores-Estrada Dana Aline P érez Camargo Maritza Ramos-Ram írez Jorge-Negueb Mart ínez-Hernández Luis F O ñate-Ocaña Pamela Soberanis Pina Andr és F Cardona Oscar Arri Source Type: research

Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Oncologist. 2024 Apr 1:oyae044. doi: 10.1093/oncolo/oyae044. Online ahead of print.ABSTRACTWe analyzed the antitumor activity of platinum-based chemotherapies and then immune checkpoint inhibitors (ICI) in all-comers patients with solid tumors having a somatic DNA damage repair gene alteration (DDR-GA) identified through a prospective precision medicine study (NCT02534649). Each DDR-GA was classified as pathogenic (Pa), probably pathogenic (PPa), and unknown pathogenicity (UPa) according to OncoKB and ClinVAR databases. Between January 2018 and May 2020, 662 patients were screened. One hundred ninety-nine tumors with DDR-G...
Source: The Oncologist - April 1, 2024 Category: Cancer & Oncology Authors: Cl ément Chabot Antoine Italiano Amandine Cromb é Isabelle Soubeyran Yech'an Laizet Emmanuel Khalifa Sophie Cousin Source Type: research

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma
CONCLUSIONS: This is the largest prospective anti-PD-1 trial with mature data in advanced melanoma in China. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy. Immunotherapy seems less efficacious for long-term responders with mucosal primaries as rechallenge therapy.PMID:38547052 | DOI:10.1093/oncolo/oyae045 (Source: The Oncologist)
Source: The Oncologist - March 28, 2024 Category: Cancer & Oncology Authors: Bixia Tang Rong Duan Xiaoshi Zhang Shuikui Qin Di Wu Jing Chen Hong Yao Zhihong Chi Jun Guo Xieqiao Yan Source Type: research

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma
CONCLUSIONS: This is the largest prospective anti-PD-1 trial with mature data in advanced melanoma in China. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy. Immunotherapy seems less efficacious for long-term responders with mucosal primaries as rechallenge therapy.PMID:38547052 | DOI:10.1093/oncolo/oyae045 (Source: The Oncologist)
Source: The Oncologist - March 28, 2024 Category: Cancer & Oncology Authors: Bixia Tang Rong Duan Xiaoshi Zhang Shuikui Qin Di Wu Jing Chen Hong Yao Zhihong Chi Jun Guo Xieqiao Yan Source Type: research

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma
CONCLUSIONS: This is the largest prospective anti-PD-1 trial with mature data in advanced melanoma in China. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy. Immunotherapy seems less efficacious for long-term responders with mucosal primaries as rechallenge therapy.PMID:38547052 | DOI:10.1093/oncolo/oyae045 (Source: The Oncologist)
Source: The Oncologist - March 28, 2024 Category: Cancer & Oncology Authors: Bixia Tang Rong Duan Xiaoshi Zhang Shuikui Qin Di Wu Jing Chen Hong Yao Zhihong Chi Jun Guo Xieqiao Yan Source Type: research

Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma
CONCLUSIONS: This is the largest prospective anti-PD-1 trial with mature data in advanced melanoma in China. Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy. Immunotherapy seems less efficacious for long-term responders with mucosal primaries as rechallenge therapy.PMID:38547052 | DOI:10.1093/oncolo/oyae045 (Source: The Oncologist)
Source: The Oncologist - March 28, 2024 Category: Cancer & Oncology Authors: Bixia Tang Rong Duan Xiaoshi Zhang Shuikui Qin Di Wu Jing Chen Hong Yao Zhihong Chi Jun Guo Xieqiao Yan Source Type: research

Correction to: Comparing Drug Shortages Experienced by Institutions With National Metrics
Oncologist. 2024 Mar 26:oyae058. doi: 10.1093/oncolo/oyae058. Online ahead of print.NO ABSTRACTPMID:38531814 | DOI:10.1093/oncolo/oyae058 (Source: The Oncologist)
Source: The Oncologist - March 27, 2024 Category: Cancer & Oncology Source Type: research